Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients

International Journal of Neuropsychopharmacology

Volumn 17, Issue 11, 2014, Pages 1729-1736

  Rasmussen, Hans ^a   Ebdrup, Bjorn H ^a   Oranje, B ^a   Pinborg, Lars H ^b   Knudsen, Gitte M ^b   Glenthoj, Birte ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Altanserin; antipsychotic induced weight gain; first episode schizophrenia; PET; quetiapine; receptor binding

Indexed keywords

3 METHYLSPIPERONE C 11; ALTANSERIN F 18; CITALOPRAM; DOPAMINE 2 RECEPTOR; FLUOXETINE; QUETIAPINE; RADIOLIGAND; SEROTONIN 2A RECEPTOR; SETOPERONE F 18; TRACER; UNCLASSIFIED DRUG; VOLINANSERIN C 11; ALTANSERIN; DIBENZOTHIAZEPINE DERIVATIVE; KETANSERIN; NEUROLEPTIC AGENT; PROTEIN BINDING; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SELECTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; MENTAL PATIENT; NEOCORTEX; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; STEADY STATE; VOLUME OF DISTRIBUTION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; SCINTISCANNING; THREE DIMENSIONAL IMAGING; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; KETANSERIN; MALE; NEOCORTEX; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; WEIGHT GAIN; YOUNG ADULT;

EID: 84929942280     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000777     Document Type: Article

References (47)

1. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbol S, Madsen K, Frokjaer V, Martiny L, Paulson OB, Knudsen GM (2004) A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 21:1105-1113.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
3. Berridge KC (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191:391-431.
4. Bjorntorp P (1995) Endocrine abnormalities of obesity. Metabolism 44:21-23.
5. Boothman LJ, Allers KA, Rasmussen K, Sharp T (2003) Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol 139:998-1004.
6. Breisch ST, Zemlan FP, Hoebel BG (1976) Hyperphagia and obesity following serotonin depletion by intraventricular p-chlorophenylalanine. Science 192:382-385.
7. Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20.
8. Dean B (2003) The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 85:1-13.
9. De Hert M, Detraux J, van WR, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126.
10. Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baare W (2010) Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci 35:95-104.
11. Ebdrup BH, Rasmussen H, Arnt J, Glenthoj B (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs 20:1211-1223.
12. Erritzoe D, Frokjaer VG, Haugbol S, Marner L, Svarer C, Holst K, Baaré W, Rasmussen PM, Madsen J, Paulson OB, Knudsen GM (2009) Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage 46:23-30.
13. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, Gansler T, Glynn T, Smith RA, Taubert K, Thun MJ (2004) Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109:3244-3255.
14. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-126.
15. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L (2001) D(2) and 5HT (2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11:105-110.
16. Gray JA, Roth BL (2001) Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451.
17. Grubb F (1969) Procedures for detecting outlying observations in samples. Technometrics 469-479.
18. Haugbol S, Pinborg LH, Arfan HM, Frokjaer VM, Madsen J, Dyrby TB, Svarer C, Knudsen GM (2007) Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 34:910-915.
19. Haupt DW (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16(Suppl. 3):S149-S155.
20. Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rosch F (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem 17:2989-3002.
21. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389-409.
22. Huang XF, Han M, Huang X, Zavitsanou K, Deng C (2006) Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behav Brain Res 171:355-362.
23. Huang XF, Huang X, Han M, Chen F, Storlien L, Lawrence AJ (2004) 5-HT2A/2C receptor and 5-HT transporter densities in mice prone or resistant to chronic high-fat diet-induced obesity: a quantitative autoradiography study. Brain Res 1018:227-235.
24. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
25. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559.
26. Kaye WH, Frank GK, Bailer UF, Henry SE, Meltzer CC, Price JC, Mathis CA, Wagner A (2005) Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav 85:73-81.
27. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001.
28. Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM (2005) Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 58:249-257.
29. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158.
30. Laursen TM, Nordentoft M, Mortensen PB (2013) Excess early mortality in Schizophrenia. Annu Rev Clin Psychol 10:425-448.
31. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
32. Lewis R, Kapur S, Jones C, DaSilva J, Brown GM, Wilson AA, Houle S, Zipursky RB (1999) Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 156:72-78.
33. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27-35.
34. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1):1-93.
35. Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298:1794-1796.
36. Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614-1641.
37. Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbol S, Madsen J, Knudsen GM (2003) Quantification of 5-HT2A receptors in the human brain using [18F] altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab 23:985-996.
38. Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA (2001) Analyses of [(18)F] altanserin bolus injection PET data. II: consideration of radio-labeled metabolites in humans. Synapse 41:11-21.
39. Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, Baare W, Svarer C, Lublin H, Knudsen GM, Glenthoj B (2010) Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 67:9-16.
40. Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baare WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B (2011) Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 213:583-592.
41. Ricca V, Nacmias B, Cellini E, Di BM, Rotella CM, Sorbi S (2002) 5-HT2A receptor gene polymorphism and eating disorders. Neurosci Lett 323:105-108.
42. Roerig JL, Steffen KJ, Mitchell JE (2011) Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25:1035-1059.
43. Rosmond R, Bouchard C, Bjorntorp P (2002) 5-HT2A receptor gene promoter polymorphism in relation to abdominal obesity and cortisol. Obes Res 10:585-589.
44. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123-1131.
45. Sharp T, Boothman L, Raley J, Queree P (2007) Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 28:629-636.
46. Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB (1999) Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol 26:601-608.
47. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546.